Nature Communications (Dec 2023)

Genes with epigenetic alterations in human pancreatic islets impact mitochondrial function, insulin secretion, and type 2 diabetes

  • Tina Rönn,
  • Jones K. Ofori,
  • Alexander Perfilyev,
  • Alexander Hamilton,
  • Karolina Pircs,
  • Fabian Eichelmann,
  • Sonia Garcia-Calzon,
  • Alexandros Karagiannopoulos,
  • Hans Stenlund,
  • Anna Wendt,
  • Petr Volkov,
  • Matthias B. Schulze,
  • Hindrik Mulder,
  • Lena Eliasson,
  • Sabrina Ruhrmann,
  • Karl Bacos,
  • Charlotte Ling

DOI
https://doi.org/10.1038/s41467-023-43719-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Epigenetic dysregulation may influence disease progression. Here we explore whether epigenetic alterations in human pancreatic islets impact insulin secretion and type 2 diabetes (T2D). In islets, 5,584 DNA methylation sites exhibit alterations in T2D cases versus controls and are associated with HbA1c in individuals not diagnosed with T2D. T2D-associated methylation changes are found in enhancers and regions bound by β-cell-specific transcription factors and associated with reduced expression of e.g. CABLES1, FOXP1, GABRA2, GLR1A, RHOT1, and TBC1D4. We find RHOT1 (MIRO1) to be a key regulator of insulin secretion in human islets. Rhot1-deficiency in β-cells leads to reduced insulin secretion, ATP/ADP ratio, mitochondrial mass, Ca2+, and respiration. Regulators of mitochondrial dynamics and metabolites, including L-proline, glycine, GABA, and carnitines, are altered in Rhot1-deficient β-cells. Islets from diabetic GK rats present Rhot1-deficiency. Finally, RHOT1methylation in blood is associated with future T2D. Together, individuals with T2D exhibit epigenetic alterations linked to mitochondrial dysfunction in pancreatic islets.